id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2005-N-0345-0006,FDA,FDA-2005-N-0345,Semiannual Regulatory Agenda,Proposed Rule,Approval,2014-01-25T05:00:00Z,2014,1,2014-01-25T05:00:00Z,,2014-01-26T00:26:41Z,2013-29632,0,0,0900006481527db7
FDA-2005-N-0345-0002,FDA,FDA-2005-N-0345,"Distribution of Certain Drug Products by Registered Blood Establishments and Comprehensive Hemophilia Diagnostic Treatment Centers That Qualify as Health Care Entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; Policies, Requirements and Administrative Procedures",Notice,Notice of Final Rule,2008-10-09T04:00:00Z,2008,10,,,2015-11-04T15:36:44Z,E8-24050,0,0,09000064807410a4
FDA-2005-N-0345-0001,FDA,FDA-2005-N-0345,"Distribution of Blood Derivatives by Registered Blood Establishments that Qualify as Health Care Entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; Policies, Requirements and Administrative Procedures; Proposed Rule",Proposed Rule,Notice of Proposed Rulemaking (NPRM),2006-02-02T05:00:00Z,2006,2,2006-01-31T05:00:00Z,2006-05-03T03:59:59Z,2025-10-16T22:13:32Z,E6-1225,0,0,0900006480449864